Abstract
Background and aims: The reduced fucosylation in the spike glycoprotein of SARS-CoV-2 and the IgG antibody has been observed in COVID-19. However, the clinical relevance of α-l-fucosidase, the enzyme for defucosylation has not been discovered.
Materials and methods: 585 COVID-19 patients were included to analyze the correlations of α-l-fucosidase activity with the nucleic acid test, IgM/IgG, comorbidities, and disease progression.
Results: Among the COVID-19 patients, 5.75% were double-negative for nucleic acid and antibodies. All of them had increased α-l-fucosidase, while only one had abnormal serum amyloid A (SAA) and C-reactive protein (CRP). The abnormal rate of α-l-fucosidase was 81.82% before the presence of IgM, 100% in the presence of IgM, and 66.2% in the presence of IgG. 73.42% of patients with glucometabolic disorders had increased α-l-fucosidase activity and had the highest mortality of 6.33%. The increased α-l-fucosidase was observed in 55.8% of non-severe cases and 72.9% of severe cases, with an odds ratio of 2.118. The α-l-fucosidase mRNA was irrelevant to its serum activity.
Conclusion: The change in α-l-fucosidase activity in COVID-19 preceded the IgM and SAA and showed a preferable relation with glucometabolic disorders, which may be conducive to virus invasion or invoke an immune response against SARS-CoV-2.
Keywords: Clinical relevance; Comorbidities; Coronavirus disease 2019 (COVID-19); Serological antibodies; α-l-fucosidase.
【저자키워드】 Comorbidities, Coronavirus disease 2019 (COVID-19), Clinical relevance, Serological antibodies, α-l-fucosidase., 【초록키워드】 COVID-19, antibodies, SARS-CoV-2, IgG, IgM, Coronavirus disease 2019, immune response, Mortality, spike glycoprotein, C-reactive protein, CRP, virus, Disease progression, nucleic acid, serum, IgG antibody, IgM/IgG, mRNA, nucleic acid test, clinical, Patient, severe cases, correlation, COVID-19 patients, Odds ratio, COVID-19 patient, Invasion, disorders, enzyme, serum amyloid, material, disorder, Non-severe case, SAA, highest, reduced, 【제목키워드】 Infection, serum, clinical, the SARS-CoV-2,